AngioDynamics Says FDA Approves IDE Application To Initiate RELIEF Study Evaluating NanoKnife IRE Platform As Minimally Invasive Treatment Option For Men With Benign Prostatic Hyperplasia

Loading news article.

AngioDynamics Says FDA Approves IDE Application To Initiate RELIEF Study Evaluating NanoKnife IRE Platform As Minimally Invasive Treatment Option For Men With Benign Prostatic Hyperplasia | WAPE

AngioDynamics Says FDA Approves IDE Application To Initiate RELIEF Study Evaluating NanoKnife IRE Platform As Minimally Invasive Treatment Option For Men With Benign Prostatic Hyperplasia

Article summary

Related companies

Comments —